417 related articles for article (PubMed ID: 29409576)
21. Overdose Education and Naloxone for Patients Prescribed Opioids in Primary Care: A Qualitative Study of Primary Care Staff.
Binswanger IA; Koester S; Mueller SR; Gardner EM; Goddard K; Glanz JM
J Gen Intern Med; 2015 Dec; 30(12):1837-44. PubMed ID: 26055224
[TBL] [Abstract][Full Text] [Related]
22. Naloxone Administration for Opioid Overdose Reversal in the Prehospital Setting: Implications for Pharmacists.
Weaver L; Palombi L; Bastianelli KMS
J Pharm Pract; 2018 Feb; 31(1):91-98. PubMed ID: 28399697
[TBL] [Abstract][Full Text] [Related]
23. Naloxone Counseling for Harm Reduction and Patient Engagement.
Han JK; Hill LG; Koenig ME; Das N
Fam Med; 2017 Oct; 49(9):730-733. PubMed ID: 29045991
[TBL] [Abstract][Full Text] [Related]
24. A nationwide pharmacy chain responds to the opioid epidemic.
Shafer E; Bergeron N; Smith-Ray R; Robson C; O'Koren R
J Am Pharm Assoc (2003); 2017; 57(2S):S123-S129. PubMed ID: 28163028
[TBL] [Abstract][Full Text] [Related]
25. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
Stopka TJ; Donahue A; Hutcheson M; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
[TBL] [Abstract][Full Text] [Related]
26. The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.
Burrell A; Ethun L; Fawcett JA; Rickard-Aasen S; Williams K; Kearney SM; Pringle JL
J Am Pharm Assoc (2003); 2017; 57(2S):S73-S77.e1. PubMed ID: 28109629
[TBL] [Abstract][Full Text] [Related]
27. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction.
Hill LG; Evoy KE; Reveles KR
J Am Pharm Assoc (2003); 2019; 59(6):779-782. PubMed ID: 31402146
[TBL] [Abstract][Full Text] [Related]
28. What is known about community pharmacy supply of naloxone? A scoping review.
Nielsen S; Van Hout MC
Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
[TBL] [Abstract][Full Text] [Related]
29. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
30. Measuring a Crisis: Questioning the Use of Naloxone Administrations as a Marker for Opioid Overdoses in a Large U.S. EMS System.
Grover JM; Alabdrabalnabi T; Patel MD; Bachman MW; Platts-Mills TF; Cabanas JG; Williams JG
Prehosp Emerg Care; 2018; 22(3):281-289. PubMed ID: 29297739
[TBL] [Abstract][Full Text] [Related]
31. A Laboratory Session to Prepare Pharmacy Students to Manage the Opioid Crisis Situation.
Donohoe KL; Raghavan A; Tran TT; Alotaibi FM; Powers KE; Frankart LM
Am J Pharm Educ; 2019 Sep; 83(7):6988. PubMed ID: 31619820
[No Abstract] [Full Text] [Related]
32. A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice.
Mueller SR; Walley AY; Calcaterra SL; Glanz JM; Binswanger IA
Subst Abus; 2015; 36(2):240-53. PubMed ID: 25774771
[TBL] [Abstract][Full Text] [Related]
33. The implementation of a naloxone rescue program in university students.
Panther SG; Bray BS; White JR
J Am Pharm Assoc (2003); 2017; 57(2S):S107-S112.e2. PubMed ID: 28063773
[TBL] [Abstract][Full Text] [Related]
34. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
Davis CS; Carr D
Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
[TBL] [Abstract][Full Text] [Related]
35. Naloxone administration for suspected opioid overdose: An expanded scope of practice by a basic life support collegiate-based emergency medical services agency.
Jeffery RM; Dickinson L; Ng ND; DeGeorge LM; Nable JV
J Am Coll Health; 2017 Apr; 65(3):212-216. PubMed ID: 28059635
[TBL] [Abstract][Full Text] [Related]
36. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose.
Goldberg SA; Dworkis DA; Liao VT; Eyre AJ; Albert J; Fawcett MM; Narovec CM; DiClemente J; Weiner SG
Prehosp Emerg Care; 2018; 22(6):788-794. PubMed ID: 29723076
[TBL] [Abstract][Full Text] [Related]
38. Opioid Overdose and Naloxone Kit Distribution: A Quality Assurance Educational Program in the Primary Care Setting.
Lockett TL; Hickman KL; Fils-Guerrier BJ; Lomonaco M; Maye JP; Rossiter AG
J Addict Nurs; 2018; 29(3):157-162. PubMed ID: 30180000
[TBL] [Abstract][Full Text] [Related]
39. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219
[TBL] [Abstract][Full Text] [Related]
40. Development and implementation of procedures for outpatient naloxone prescribing at a large academic medical center.
Zschoche JH; Nesbit S; Murtaza U; Sowell A; Waldfogel JM; Arwood N; Rush J; McNamara L; Swarthout M; Nesbit T; Ortmann M
Am J Health Syst Pharm; 2018 Nov; 75(22):1812-1820. PubMed ID: 30076167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
